Product Name: PRPF4B (846-852) pY849
Product Number: PE-04BBQ00
| Size: | 200 µg | Price: | 35.00 | |
| 1 mg | $US | 70.00 |
Peptide Name: PRPF4B (846-852) pY849
Product Use: This phosphopeptide may be useful as a substrate for screening the phosphatase activity of protein phosphatases and for epitope mapping of phosphosite-specific antibodies. The peptide sequence is located in the protein kinase catalytic domain activation T-loop between subdomains VII and VIII. Y849 phosphorylation stimulates phosphotransferase activity.
Peptide Production Method: Solid-phase peptide synthesis
Peptide Origin: Homo sapiens
Peptide Sequence: ITP-pY-LVS
Peptide Modifications N Terminus: Free amino
Peptide Modifications C Terminus: Amide
Peptide Modifications Other: Phosphorylated
Product Use: This phosphopeptide may be useful as a substrate for screening the phosphatase activity of protein phosphatases and for epitope mapping of phosphosite-specific antibodies. The peptide sequence is located in the protein kinase catalytic domain activation T-loop between subdomains VII and VIII. Y849 phosphorylation stimulates phosphotransferase activity.
Peptide Production Method: Solid-phase peptide synthesis
Peptide Origin: Homo sapiens
Peptide Sequence: ITP-pY-LVS
Peptide Modifications N Terminus: Free amino
Peptide Modifications C Terminus: Amide
Peptide Modifications Other: Phosphorylated
Peptide Molecular Mass Calculated: 870.92 Da
Peptide Purity Percent after Synthesis and Purification: >90
Peptide Appearance: White powder
Peptide Form: Solid
Storage Conditions: -20°C
Storage Stability: stable
Peptide Purity Percent after Synthesis and Purification: >90
Peptide Appearance: White powder
Peptide Form: Solid
Storage Conditions: -20°C
Storage Stability: stable
Scientific Background: PRPF4B (PRP4) is a protein-serine/threonine kinase of the CMGC group and DYRK family. It is known to regulate pre-mRNA splicing. Identified substrates for PRPF4B include splicing factors SF2, PRPF6, and PRPF31 as well as the KLF13 and Elk1 transcription factors. The enzymatic activity of PRP4 is required for viability of pancreatic, colon and large B-cell lymphoma cancer cell lines (PubMed: 24003220). Inhibition of PRP4 activity by shRNAs was shown to resensitize chemoresistant human ovarian and breast cancer to paclitaxel treatment.
© Kinexus Bioinformatics Corporation 2017